Picture of Silence Therapeutics logo

SLNCF Silence Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

REG - FTSE Russell Silence Therapeutics Serica Energy PLC Pantheon Resources - Silence Therapeutics

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211125:nRSY6423Ta&default-theme=true

RNS Number : 6423T  FTSE Russell  25 November 2021

 

Silence Therapeutics (UK): Constituent Deletion

Changes in FTSE UK Index Series

25 November 2021

 Subject to the expected cancellation of trading on AIM for Silence
 Therapeutics (UK, constituent), please see details of affected indexes and
 effective dates below:

 

 Index                     Effective From

Start of Trading
 FTSE AIM UK 50 Index      30 November 2021
 FTSE AIM 100 Index        30 November 2021
 FTSE AIM All-Share Index  30 November 2021

 

 

 

 

 

 

 For further information please contact FTSE Russell Client Services at
 info@ftserussell.com or call:

Australia  +1800 653 680
 Hong Kong  +852 2164 3333
 Japan      +81 3 4563 6346
 London     +44 (0) 20 7866 1810
 New York   +1866 551 0617

 

 Alternatively please visit our website at www.ftserussell.com

 Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
 © 2021 FTSE Russell

 

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2021 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FTSDKPBDPBDDCDB

Recent news on Silence Therapeutics

See all news